Built by Operators, Not Observers.

Operator and company-builder with experience spanning early-stage biotech formation, capital structure design, and therapeutic asset development. Has led organizations from concept through capitalization and has been a principal in significant biopharma transactions — including a multi-hundred-million-dollar asset acquisition that brought a clinical-stage program from an academic spinout into a development-stage company. Brings a track record of building lean, execution-focused teams around high-value science and deep familiarity with the governance structures required to close complex academic-to-industry transactions efficiently.

Drug development executive with an exceptional operational track record — having led nearly 100 IND programs and shepherded multiple assets through commercial launch. Brings end-to-end development experience from preclinical planning through regulatory submission, approval, and market entry. Has structured pharma partnerships, licensing transactions, and strategic alliances across therapeutic modalities, with particular depth in academic institution relationships and early-stage asset transactions. Oversees day-to-day operations and the vendor management infrastructure that powers Perago's virtual execution model.

Seasoned drug developer with deep experience in CNS and neuroscience and a track record of advancing programs across multiple indications and modalities — from small molecules to biologics. Has led scientific diligence, target validation, and translational development planning from preclinical through IND and into clinical execution. Brings established relationships within the academic neuroscience community and a rigorous framework for evaluating preclinical-to-clinical translatability.

Scientist and innovation strategist with a background spanning academic drug discovery, translational research design, and early-stage program development. Applies AI-driven approaches to transcriptomic target identification, integrating computational systems into the asset sourcing and diligence workflow. Contributes scientific input across the portfolio — from initial asset triage and mechanism evaluation through biomarker strategy and experimental design — serving as the bridge between academic discovery teams and Perago's development engine.

Senior executive and board-level leader with decades of experience across life sciences, institutional investment, and corporate governance. Has served in chairman and board roles across multiple healthcare and biopharmaceutical companies, with a career spanning capital formation, strategic oversight, and organizational leadership at scale. Chairs Perago's Investment Committee, bringing the institutional credibility and governance discipline required to steward a portfolio company through fundraising, asset development, and strategic exit.